Detailed answers about DR CHIMAOBI AZUBUIKE CLINICAL SERVICES LIMITED, including incorporation, status, business activity, and accounts information.
When was DR CHIMAOBI AZUBUIKE CLINICAL SERVICES LIMITED founded?
DR CHIMAOBI AZUBUIKE CLINICAL SERVICES LIMITED was officially incorporated on 8 June 2026 and is registered under company number 17267145. Incorporation establishes the company as a legal entity registered at Companies House, allowing it to trade, enter contracts, and operate under UK company law.
What type of company is DR CHIMAOBI AZUBUIKE CLINICAL SERVICES LIMITED?
Private Limited Company. This classification indicates the legal structure of the company, which determines the way it is governed, its liability, and regulatory obligations. A private limited company (Ltd) limits the personal liability of its shareholders.
What is the current status of DR CHIMAOBI AZUBUIKE CLINICAL SERVICES LIMITED?
DR CHIMAOBI AZUBUIKE CLINICAL SERVICES LIMITED's current status is Active. The company status indicates whether it is actively trading, dormant, or has been dissolved. Maintaining an active status is essential for legally conducting business, filing accounts, and maintaining credibility with partners and lenders.
What does DR CHIMAOBI AZUBUIKE CLINICAL SERVICES LIMITED do?
DR CHIMAOBI AZUBUIKE CLINICAL SERVICES LIMITED operates in the following sector: 86210 - General medical practice activities. This provides insight into the company's primary business activity and industry focus.
What is DR CHIMAOBI AZUBUIKE CLINICAL SERVICES LIMITED's registered address?
The registered office address of DR CHIMAOBI AZUBUIKE CLINICAL SERVICES LIMITED is 70 Queen Street, Normanton, England, WF6 2BU. This is the official address filed with Companies House for legal and statutory correspondence.
Is DR CHIMAOBI AZUBUIKE CLINICAL SERVICES LIMITED financially stable?
Financial accounts for DR CHIMAOBI AZUBUIKE CLINICAL SERVICES LIMITED are not currently available. Without filed accounts, it is more difficult to assess the company's financial stability and trading performance.